1. INTRODUCTION
===============

Oxidative stress is one of the mechanisms involved in ischemic brain injury induced by ischemia-reperfusion \[[@R1],[@R2]\]. In addition to the direct cytotoxic effects of lipid peroxidation, oxidative DNA damage occurs immediately after ischemia-reperfusion and leads to ischemic brain injury, as reflected by neural death and brain edema \[[@R3]-[@R7]\]. Thus, the burst of free radicals is thought to be associated with stroke severity. However, it remains uncertain how to evaluate the association between increased oxidative stress and functional outcomes of patients. In the presence of oxidative stress, reactive oxygen species, including superoxide anion radicals, hydrogen peroxide, and hydroxyl radicals, can cause oxidative damage to lipids, proteins, and nucleic acids \[[@R8]\]. During oxidative stress, DNA is constantly being damaged and oxidatively modified. Nuclear and mitochondrial DNA in tissues and blood lymphocytes are typical sites of oxidation damage \[[@R8]\].

The oxidatively modified product 8-hydroxy-2-deoxyguanosine (8-OHdG) is one of the predominant forms of free radical-induced lesions of DNA. 8-OHdG can be detected in human tissues or blood samples. Because oxidative DNA lesions, i.e., oxidized nucleosides and bases, are reasonably water soluble and excreted into the urine without being further metabolized, urinary 8-OHdG is considered an important biomarker of generalized and cellular oxidative stress \[[@R9]\]. In fact, urinary 8-OHdG levels have been most frequently measured to indicate the extent of oxidative damage, since it is a non-invasive and technically less involved procedure \[[@R10]\].

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, Mitsubishi Pharma Corp), a novel radical scavenger, has been shown to inhibit lipid peroxidation and vascular endothelial cell injury and ameliorate brain edema, tissue injury, delayed neuronal death, and neurological deficits \[[@R11]-[@R13]\]. Edaravone is the first neuroprotective agent to be approved for clinical use in Japan \[[@R14]\]. The effect of edaravone on ischemic processes has been investigated experimentally, but no data is available on its effects on oxidative stress markers in the human ischemic brain.

In the present study, we examined oxidative stress in patients with acute ischemic stroke by determining the changes in urinary 8-OHdG, a maker of oxidative damage. We evaluated the relationships between 8-OHdG levels, stroke subtypes, and clinical outcomes based on the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) at discharge. The effect of edaravone on oxidative damage was also examined.

2. MATERIALS AND METHODOLOGY
============================

2.1. Patients
-------------

Forty-four patients (males: 26, females: 18; age: 29--92 years, mean ± SD: 71.3 ± 10.9 years) with acute cerebral infarction from July 2007 to February 2008 were enrolled in this study in the Department of Internal Medicine at Seikeikai Hospital, Sakai, Osaka. All patients underwent an MRI examination immediately at admission, and diagnosis was based on clinical findings. An NIHSS score was assigned both at admission and upon discharge to determine neurological deficits \[[@R15]\]. The mRS was also used to assess their clinical outcomes at discharge \[[@R16]\]. Conventional vascular risk factors (hypertension, diabetes mellitus, hyperlipidemia), atrial fibrillation, body mass index (BMI)，and previous stroke were evaluated. Patients whose data could not be evaluated at the time of stroke onset and those with hemorrhagic infarction were excluded from this study. Stroke subtypes were defined according to the NINDS-III classification system \[[@R17]\]. Of the 44 patients, 9 (20.5%) had lacunar, 22 (50%) had atherothrombotic, and 13 (29.5%) had cardioembolic infarctions. Of these, 34 patients were treated with edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, a free-radical scavenge, Mitsubishi Pharma Corp) in addition to routine treatment within 24 h of onset of symptoms (60 mg/day for 14 days). The remaining patients did not receive edaravone, because this medical agent is relative contraindications for patients with chronic renal failure and has been approved for the treatment of acute ischemic stroke within 24 hours after onset. All patients with lacunar and atherothrombotic infarctions received sodium ozagrel, a thromboxane A2 synthetase inhibitor, intravenously (160 mg/day for 10--14 days), and 35 patients received glycerol (250--500 ml/day for 3--7 days). There was no patient with thrombolytic therapy in this study. This study received institutional review board approval and informed consent was obtained according to the Declaration of Helsinki.

2.2. Measurement of Urinary 8-OHdG
----------------------------------

Urine samples were collected on admission (Day 0) and 7 days after admission (Days 7). Urinary 8-OHdG concentrations were measured using an enzyme-linked immunosorbent assay (8-Hydroxydeoxyguanosine Check; Japan Institute for the Control of Aging, Shizuoka, Japan) \[[@R18]\]. Results were expressed as ratios to the creatinine contents (per mg Cr) measured in the same samples.

Moreover, we evaluated the rate of change of oxidative stress(Δ 8-OHdG) as: Δ 8-OHdG (%) = (8-OHdG on Day 7 8-OHdG on Day 0)/8-OHdG on Day 0.

2.3. Statistical Analysis
-------------------------

Results are given as means ± SEs. Categorical variables were compared using the χ^2^ test and continuous variables were compared using the Mann-Whitney test or ANOVA, followed by Scheffe's post hoc test. Significance levels were set at *P*\< 0.05.

3. RESULTS
==========

3.1. Urinary 8-OHdG and Relationships to Subtypes of Ischemic Stroke and Risk Factors for Arteriosclerosis
----------------------------------------------------------------------------------------------------------

Patients clinical profiles according to ischemic stroke subtypes are summarized in Table **[1](#T1){ref-type="table"}**. There were no significant differences with respect to age or history of previous stroke among the 3 groups. Prevalence of auricular fibrillation was the highest among those with cardiac embolism. Regarding risk factors for arteriosclerosis, prevalence of hypertension was the highest in patients with lacunar infarction, and incidence of diabetes mellitus and hyperlipidemia were the highest in those with atherothrombotic infarctions. The number of arteriosclerosis risk factors was also higher in lacunar and artherothrombotic infarction groups compared to cardioembolic infarction group. The cardioembolic infarction group had a shorter time from onset to arrival, higher baseline NIHSS, and longer length of stay compared to the other 2 groups. There were no significant differences in 8-OHdG concentrations on Day 0 among the 3 groups, and 8-OHdG concentrations increased on Day 7 in all groups (Table **[1](#T1){ref-type="table"}**)

We investigated the relationship between Δ 8-OHdG and stroke subtype, lacunar, atherothrombotic, and cardioembolic infarction. As shown in Fig. (**[1](#F1){ref-type="fig"}**), the increase in Δ 8-OHdG in the atherothrombotic infarction group was significantly greater than that in the lacunar infarction group (33.8 vs 6.3, p = 0.048). It was remarkable that Δ 8-OHdG in the atherothrombotic infarction group tended to be increased than that in the cardioembolic infarction group in spite of smaller volume of infarction for atherothrombotic infarction group. As shown in Table **[1](#T1){ref-type="table"}**, patients with atherothrombotic infarction had more risk factors for arteriosclerosis than other groups. Also, half of patients with atherothrombotic infarction showed poor outcome (mRS ≥3). Since it was assumed that these risk factors might influence on a production of the oxidative stress, we investigated whether risk factors for arteriosclerosis, hyperetension, diabetes mellitus and hyperlipidemia, and body mass index (BMI) would involve the Δ 8-OHdG. As results, patients with diabetes mellitus, hyperlipidemia, or high BMI showed the increased 8-OHdG (p = 0.047, p = 0.037, p = 0.033, Fig. **[2](#F2){ref-type="fig"}**). These findings suggest that more oxidative stress would be generated in stroke patients with more risk factors for arteriosclerosis, reflecting poor outcome.

3.2. Relationship Between Clinical Outcome and Urinary 8-OHdG
-------------------------------------------------------------

Next, we investigated whether urinary 8-OHdG concentrations reflected the severity and outcome of ischemic stroke. When comparing patients with a poor outcome (mRS ≥3) and a good outcome (mRS ≤2), no significant differences were observed for age, history of previous stroke and atrial fibrillation, and prevalence of risk factors for arteriosclerosis (Table **[2](#T2){ref-type="table"}**). Among patients with cardioembolic infarctions, significantly more number of patients had a poor outcome. Accordingly, NIHSS scores at admission were higher and the time from onset to arrival was shorter in patients with a poor outcome. There was no significant difference in 8-OHdG concentrations on Day 0 between patients with poor and good outcomes, and 8-OHdG concentrations increased on Day 7 in both groups (Table **[2](#T2){ref-type="table"}**). As shown in Fig. (**[3](#F3){ref-type="fig"}**), patients with a poor outcome had a significantly increased Δ 8-OHdG compared to those with a good outcome (2.54 vs 39.44, p = 0.004). These findings suggested that the biochemical changes related to 8-OHdG and oxidative stress may be considered a marker of ischemic brain injury and clinical outcome of ischemic stroke.

3.3. Effect of Edaravone Treatment on Urinary Δ 8-OHdG
------------------------------------------------------

On comparing the patients treated with or without edaravone, no significant differences were observed for age, stroke subtypes, and risk factors for arteriosclerosis (Table **[3](#T3){ref-type="table"}**). Based on NIHSS scores, patients who received edaravone tended to be classified as more severe at admission compared to those who did not receive edaravone (11.1 vs 6.1); however, both showed equivalent mRS scores at discharge (2.5 vs 2.7). Although there was no significant difference in Δ 8-OHdG levels between patients treated with or without edaravone, Δ 8-OHdG in patients who received edaravone tended to be reduced compared to those who did not receive edaravone within the atherothrombotic infarction group (23.5 vs 46.5, p = 0.433, Fig. **[4](#F4){ref-type="fig"}**).

4. DISCUSSION
=============

In order to evaluate ischemic brain damage, numerous biomarkers related to oxidative stress, such as nitric oxide, matrix metalloproteinase-9, S100β, and oxidized LDL, have been investigated \[[@R19]-[@R22]\]. The main finding of our study is the demonstration of an association between urinary 8-OHdG and ischemic stroke. The present study provides evidence that Δ 8-OHdG, specifically the rate of change of urinary 8-OHdG, may be considered a marker of tissue injury in brain ischemia. In fact, mRS scores (i.e., clinical outcomes at discharge) showed a significant correlation with Δ 8-OHdG (Fig. **[3](#F3){ref-type="fig"}**). These findings suggest that Δ 8-OHdG may act as a mediator during the evolution of ischemic damage.

In all 3 subtypes of ischemic stroke, lacunar, atherothrombotic, and cardioembolic infarctions, urinary 8-OHdG levels increased on Day 7. When we compared the rate of change of urinary 8-OHdG (Δ 8-OHdG), Δ 8-OHdG was significantly higher in patients in the atherothrombotic infarction group than that of patients in the lacunar infarction group (Fig. **[1](#F1){ref-type="fig"}**). Moreover, Δ 8-OHdG of patients in the lacunar infarction group tended to be lower than that of patients in the cardioembolic infarction group, suggesting that a smaller infarction volume can result in lesser amounts of oxidative stress. However, the questions arise as to why Δ 8-OHdG increased more in the atherothrombotic infarction than in the cardioembolic infarction group.

Numerous studies have shown that urinary 8-OHdG is not only a biomarker of oxidative stress but also a possible risk factor for cancer, coronary heart disease, diabetes, and atherosclerosis \[[@R23],[@R24]\]. For example, elevated levels of urinary 8-OHdG have been detected in patients with diabetes mellitus or hypertension \[[@R25]\]. In human atherosclerotic plaques, increased amounts of oxidatively modified DNA and 8-OHdG are present \[[@R26]\]. Thus, DNA oxidative stress may readily occur in patients with these conditions. In this study, the atherothrombotic infarction group had more number of risk factors for arteriosclerosis, such as hypertension, diabetes mellitus, and hyperlipidemia, and the cardioembolic group had less number of risk factors than the other groups (Table **[1](#T1){ref-type="table"}**). In addition, the risk factors for arteriosclerosis such as diabetes mellitus, hyperlipidemia, and BMI influence on a production of the oxidative stress (Fig. **[2](#F2){ref-type="fig"}**). Thus, patients with atherothrombotic infarctions may have some background conditions for which 8-OHdG is easily generated, and more increased oxidative damage may cause poor outcome comparable to that of patients with cardioembolic infarctions, despite having the less infarction volume.

There is increasing evidence for the contributions of oxidative stress to ischemic brain damage in primary and secondary pathophysiological mechanisms \[[@R1],[@R2]\]. In addition to the direct cytotoxic effects of lipid peroxidation and oxidative DNA damage that occurs immediately after ischemic injury, the burst of free radicals also induces formation of inflammatory mediators through redox-mediated signaling pathways, leading to post-ischemia/reperfusion inflammatory injury \[[@R4],[@R6]\]. Therefore, the control of these 2 impacts of oxidative damage is important to achieve neuroprotection.

Recent studies demonstrated that edaravone provided neuroprotection in the integrated processes of oxidative stress-induced injury in ischemic stroke \[[@R27],[@R28]\]. Edaravone has antioxidant properties that result in suppressing lipid peroxidation products and oxidative DNA damage, as well as anti-inflammatory effects that result in reduced iNOS production \[[@R29]-[@R33]\]. Further studies by using animal model suggested that a combination therapy with edaravon and tissue plasminogen activator (rt-PA) could provide important therapeutic benefits for acute stroke patients, not only in reducing the infarct size but also in minimizing the catastrophic hemorrhagic transformation. In these studies, edaravone suppressed matrix metalloproteinase-9 (MMP-9) upreguration and hemorrhagic transformation by scavenging rt-PA-induced reactive oxidative stress derived from ischemia/reperfusion injury \[[@R34],[@R35]\].

As the present study was not a randomized trial, there could have been a bias in the selection of patients for edaravone use. However, although patients who received edaravone tended to be classified as more severe based on NIHSS scores at admission than those who did not receive edaravone, both groups showed equivalent mRS scores at discharge (Table **[3](#T3){ref-type="table"}**). Furthermore, Δ 8-OHdG levels in patients who received edaravone tended to be reduced compared to those who did not receive edaravone within the atherothrombotic infarction group (Fig. **[4](#F4){ref-type="fig"}**). Thus, edaravone treatment might provide a neuroprotective effect by reducing oxidative damage and it may contribute to limiting brain damage.

5. CONCLUSION
=============

The present study demonstrated a significant association between elevated urinary 8-OHdG levels and acute ischemic stroke, especially for those with atherothrombotic infarctions. Because Δ 8-OHdG, the rate of change of urinary 8-OHdG, showed a significant relationship to mRS scores at discharge, Δ 8-OHdG may be a useful predictor of poor outcomes after ischemic stroke. Edaravone is useful for reducing oxidative damage, especially in patients with atherothrombotic infarctions, and thus, it may contribute to limiting brain damage in patients with ischemic stroke.
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###### 

Characteristics of Patients Recruited in This Study

                                      Lacunar      Atherothrombotic   Cardioembolic   P value
  ----------------------------------- ------------ ------------------ --------------- ---------
  Age                                 74           69                 74              0.298
  Male/female                         5/4          8/14               7/6             0.826
  Previous stroke, % (n)              44 (4)       18 (4)             8 (1)           0.103
  Atrial fibrillation, % (n)          11 (1)       18 (4)             85 (11)         0.001\>
  Risk factors for arteriosclerosis                                                   
   Hypertension, % (n)                100 (9)      73 (16)            15 (2)          0.001\>
   Diabetes mellitus, % (n)           0 (0)        36 (8)             8 (1)           0.029
   Hyperlipidemia, % (n)              22 (2)       50 (11)            23 (3)          0.171
   Number of risk factors             1.2          1.6                0.5             0.002
  Time from onset to arrival (h)      19.1         16.5               5.1             0.014
  Baseline NIHSS                      4            7                  19              0.003
  mRS at discharge                    1.9          2.6                3.7             0.065
   mRS ≥3, % (n)                      33.3 (3)     50.0 (11)          84.6 (11)       0.038
  Length of stay (days)               28           29                 39              0.028
  8-OHdG concentration (ng/mgCr)                                                      
   Day 0                              15.8 ± 6.9   12.8 ± 11.7        11.8 ± 5.6      0.128
   Day 7                              16.1 ± 5.1   16.2 ± 15.5        13.0 ± 5.0      0.272

###### 

Demographics and 8-OHdG Concentrations of Patients with Good and Poor Outcomes

                                      Good (mRS ≤2)   Poor (mRS ≥3)   P value
  ----------------------------------- --------------- --------------- ---------
  Age                                 70              72              0.541
  Male/female                         12:07           13:12           0.066
  Stroke subtypes                                                     
   LAC/AT/CE (n)                       6/11/2          3/11/11        0.038
  Previous stroke, % (n)              21 (4)          20 (5)          1.000
  Atrial fibrillation, % (n)          26 (5)          44 (11)         0.344
  Risk factors for arteriosclerosis                                   
   Hypertension, % (n)                68 (13)         60 (15)         0.753
   Diabetes mellitus, % (n)           26 (5)          20 (5)          0.723
   Hyperlipidemia, % (n)              32 (6)          44 (11)         0.535
   Number of risk factors             1.3             1.2             0.697
  Baseline NIHSS                      3.7             14.1            0.001
  Time from onset to arrival (h)      15.8            12.3            0.177
  Edaravone, % (n)                    74 (14)         80 (20)         
  8-OHdG concentration (ng/mgCr)                                      
   Day 0                              12.1 ± 6.3      13.3 ± 11.2     0.538
   Day 7                              12.8 ± 6.1      17.1 ± 14.1     0.205
  Δ8-OHdG (%)                         2.54            39.44           0.004

LAC; lacunar infarction, AT; atherothrombotic infarction, CE; cardioembolic infarction

###### 

Demographics and Δ8-OHdG Concentrations of Patients Treated with or Without Edaravone

                                          Edaravone (+)   Edaravone (--)   P value
  --------------------------------------- --------------- ---------------- ---------
  Age                                     71              71               0.094
  Male/female                             21/13            5/5             0.716
  Stroke subtypes                                                          
   LAC/AT/CE (n)                          7/16/11          2/6/2           0.719
  Risk factors for arteriosclerosis                                        
   Hypertension, % (n)                    56 (19)         80 (8)           0.271
   Diabetes mellitus, % (n)               18 (6)          30 (3)           0.402
   Hyperlipidemia, % (n)                  44 (15)         10 (1)           0.067
  Atrial fibrillation, % (n)              33 (12)         40 (4)           1
  Time from onset to arrival (h)          9.5             30.3             0.037
  Baseline NIHSS (range)                  11.1 (2-37)     6.1 (1-9)        0.842
  NIHSS 14 days after admission (range)   6.3 (0-28)      3 (1-8)          0.644
  mRS at discharge                        2.5             2.7              0.597
  Medications                                                              
   Antithrombotic, % (n)                  44 (15)         80 (8)           0.076
   Glycerol, % (n)                        86 (29)         60 (6)           0.175
  Length of stay (days)                   32              29.7             0.123
  Δ8-OHdG (%)                             20.8            21.3             0.777

LAC; lacunar infarction, AT; atherothrombotic infarction, CE; cardioembolic infarction
